Company Name : Bal Pharma Limited
Address : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore – 560 052, Karnataka, India
Tel No: 91-80-41379500
Email : info@balpharma.com, hr@balpharma.com
Website : http://www.balpharma.com/
Company Profile
To improve the quality of life for patients by providing them with products which are Safe, Effective, High Quality and Affordable price.
Bal Pharma is a fully integrated and leading Indian Pharmaceutical Company specializing in Prescription drugs, Generic, OTC products, Intravenous Infusion and Bulk Actives with almost 19 years of experience behind it.
Bal Pharma’s API’s and Formulations are produced at world class manufacturing facilities. API’s are exported to Europe, Latin America, Africa, Middle East and Asian markets. Formulation products are exported to Semi-Regulated and Non Regulated markets and s strong contender for Tender business in various markets especially Asian markets.
With the new facility being set up in Uttaranchal, as per ICH and PIC guidelines to meet the requirements of USFDA and various European MOH, the company plans to enter in to Regulated Markets by 2010 and already in talks for Contract Manufacturing for clients in Regulated Markets. Successful Operations in Domestic and International markets, backed by its strength in Research and strong Infrastructure frame work have accelerated Bal Pharma’s growth from oblivience to reach a turn over of USD 25 million today. Buoyed by the past, the group has put in motion a fast track growth target and has set its sigh on sales in excess of USD 150 million by 2015.
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…